Policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002

被引:44
作者
Andersson, Karolina
Petzold, Max Gustav
Sonesson, Christian
Lonnroth, Knut
Carlsten, Anders
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Dept Social Med, SE-40530 Gothenburg, Sweden
[2] Univ Gothenburg, Stat Res Unit, Gothenburg, Sweden
[3] Nord Sch Publ Hlth, Gothenburg, Sweden
[4] Natl Corp Swedish Pharm Apoteket AB, Dept Res & Dev, Gothenburg, Sweden
关键词
health care reform; pharmaceuticals; co-payment; pharmaceutical reimbursement scheme; reference based pricing;
D O I
10.1016/j.healthpol.2006.01.007
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The last decades increasing pharmaceutical expenditures in Sweden and other western countries have created a need for reforms to reduce the trend. The aim was to analyse if reforms concerning the pharmaceutical reimbursement scheme in Sweden during the years 1986-2002 were associated with changes in cost, volume and cost per volume of pharmaceuticals. Effects of changes in the reimbursement schedule during the study period were evaluated for all registered pharmaceuticals in Sweden and for five indicator drug groups. Five policy changes during the study period were assessed. Three concerned increased patient co-payment (January 1, 1991; January 1, 1995 and June 1, 1999), one the introduction of reference based pricing and increased co-payment (January 1, 1993) and one a new structure of the reimbursement schedule (January 1, 1997). The National Corporation of Swedish Pharmacies provided pharmaceutical delivery data for all Swedish pharmacies. Possible breaks in the trend associated with the investigated reforms were analysed with linear segmented regression analysis. This showed that increased co-payments were not associated with changed level or slope of cost and volume. The new reimbursement schedule was associated with a decreased level of cost and volume, both for all drugs combined and for several of the indicator drug groups. It was also associated with an increased slope for both volume and cost in some indicator drug groups and for all drugs. Introduction of reference based pricing was associated with a reduced slope of cost/defined daily doses (DDD) in all of the indicator drug groups and for all drugs. The analysis showed that major changes in the reimbursement system such as the introduction of a new reimbursement schedule and reference based pricing were associated with reductions in cost and volume for the new reimbursement schedule and cost per volume for reference based pricing. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:231 / 243
页数:13
相关论文
共 36 条
[1]   What are the obstacles to generic substitution?: An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden [J].
Andersson, K ;
Sonesson, C ;
Petzold, M ;
Carlsten, A ;
Lönroth, K .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (05) :341-348
[2]   Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price [J].
Atella, V .
HEALTH POLICY, 2000, 50 (03) :197-218
[3]  
Cook ThomasD., 1979, Quasi-experimentation: Design analysis issues for field settings
[4]   Pharmaceutical reference prices - How do they work in practice? [J].
Dickson, M ;
Redwood, H .
PHARMACOECONOMICS, 1998, 14 (05) :471-479
[5]   The role of economic evaluation in the pricing and reimbursement of medicines [J].
Drummond, M ;
Jonsson, B ;
Rutten, F .
HEALTH POLICY, 1997, 40 (03) :199-215
[6]   European healthcare policies for controlling drug expenditure [J].
Ess, SM ;
Schneeweiss, S ;
Szucs, TD .
PHARMACOECONOMICS, 2003, 21 (02) :89-103
[7]  
*FAKT, 2005, LAK OCH HALS OCH SJU
[8]  
FOLLAND S, 2004, EC HLTH HLTH CARE, P370
[9]   The effect of changes in treatment patterns on drug expenditure [J].
Gerdtham, UG ;
Johannesson, M ;
Gunnarsson, B ;
Marcusson, M ;
Henricksson, F .
PHARMACOECONOMICS, 1998, 13 (01) :127-134
[10]   ANALYSIS OF INTERRUPTED TIME-SERIES MORTALITY TRENDS - AN EXAMPLE TO EVALUATE REGIONALIZED PERINATAL-CARE [J].
GILLINGS, D ;
MAKUC, D ;
SIEGEL, E .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1981, 71 (01) :38-46